Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zimycan distribution

This article was originally published in The Tan Sheet

Executive Summary

Ft. Worth, Texas-based Healthpoint gets exclusive rights to market Barrier Therapeutics' antifungal ointment Zimycan to healthcare institutions in the U.S. and Canada under an agreement announced Sept. 13. Barrier cites Healthpoint's tissue management division as a good match for the product. The firm announced positive Phase III trial results for the candida-associated diaper rash cream in August after licensing the drug from Johnson & Johnson, where it had failed to gain approval as an OTC (1"The Tan Sheet" Aug. 16, 2004, p. 9). Barrier's NDA for Zimycan is currently pending at FDA...

You may also be interested in...



OTC Misfire Salvaged As Rx Prospect: Barrier Touts Antifungal Zimycan Trial

Barrier Therapeutics plans to parlay Johnson & Johnson's failed over-the-counter diaper cream Zimycan into the first prescription treatment for diaper rash complicated by Candida yeast infection

RB Doubles R&D Spend In Search Of 'Game Changing’ OTC Innovation

With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.

JHL Becomes Eden And Announces Denosumab Progress

Taiwan’s JHL Biotech has rebranded itself as Eden Biologics at the same time as it has announced progress on clinical trials for its denosumab biosimilar candidate.

Topics

UsernamePublicRestriction

Register

LL1135645

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel